The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...
May 16 (Reuters) - (This May 16 story has been officially corrected by Amgen to change the pricing estimate in paragraph 4) The U.S. Food and Drug Administration on Thursday granted accelerated ...
La Food and Drug Administration (FDA) des États-Unis a accordé jeudi une autorisation accélérée au nouveau médicament d'Amgen (AMGN), le tarlatamab, commercialisé sous le nom de marque Imdelltra, pour ...
FRIDAY, MAY 17, 2024 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday approved a new drug to treat ...
Vendredi, les analystes d'Oppenheimer ont maintenu les perspectives positives d' Amgen Inc . (NASDAQ:AMGN), avec une réitération de la note "Outperform" et un objectif de prix stable de 380,00 $. Cet ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
L'étude d'Amgen et d'AstraZeneca sur les maladies pulmonaires donne des résultats mitigés 20/05 MT Amgen annonce les résultats de l'essai COURSE de phase 2a évaluant Tezspire® (Tezepelumab ...
The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi ...
The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer. Importantly, tarlatamab (Imdelltra) is only for patients who ...